Ocular FIP treatment enters a more practical era for vets

CURRENT FULL VERSION: Ocular FIP is moving from a diagnosis associated with grave prognosis to one that many veterinarians now approach with a treatment plan. The change is being driven by growing clinical experience with antiviral therapy, particularly GS-441524 and remdesivir, along with newer reviews and guidelines that treat ocular involvement as an important modifier of dose selection and case management. (pubmed.ncbi.nlm.nih.gov)

That shift follows several years of rapid change in feline medicine. FIP had long been considered almost uniformly fatal once clinical signs appeared, but published studies over the past few years have shown meaningful survival and remission rates with antiviral treatment. Practical commentary aimed at clinicians now commonly cites response rates in the 85% to 90% range, while also emphasizing that diagnosis in everyday practice is still usually presumptive and built from signalment, clinicopathologic changes, imaging, effusion analysis when present, and exclusion of major differentials rather than a single definitive test. In the U.S., access changed materially on May 10, 2024, when the FDA said it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for a specific cat patient with FIP under the conditions in Guidance for Industry #256. The agency also stressed that these compounded animal drugs are still unapproved and “not, in fact, legal,” an important distinction for veterinarians discussing treatment pathways with pet parents. (fda.gov)

For ocular disease specifically, the emerging message is that these cases often can respond, but they may not fit standard dosing assumptions. Ocular and neurologic involvement are seen disproportionately in non-effusive FIP, and ocular signs may even be the dominant presenting feature. Clinicians are being reminded to look for both anterior and posterior segment disease, including uveitis, corneal edema, keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon or fibrin, as well as tapetal or non-tapetal lesions, retinal hemorrhage, vascular tortuosity, retinal detachment, and perivascular cuffing. A 2025 systematic review found the best outcomes with GS-441524 at 5 to 10 mg/kg once daily, with dose adjustments based on disease form, severity, and the presence of neurologic or ocular signs. The current ABCD FIP guideline similarly describes ocular and neurologic involvement as factors that can justify higher dosing, and it includes case-based evidence of improvement in ocular signs, including return of vision in at least one reported case. (pubmed.ncbi.nlm.nih.gov)

The evidence base is still uneven, but it is becoming more clinically useful. A 2025 Royal Veterinary College observational case series highlighted by VetGirl examined remdesivir alone or in combination with GS-441524 in cats with ocular FIP, reinforcing that ophthalmic disease is not just a theoretical dosing modifier but a real-world treatment subgroup with measurable response. A recent retrospective JVIM study of cats treated with IV remdesivir, oral GS-441524, or both also included ocular signs among the presenting features tracked in naturally occurring FIP cases, underscoring that ophthalmic involvement is part of everyday case management, not just referral-center discussion. But the literature also shows why protocol standardization remains difficult: many early studies relied on unregulated products, and both the ABCD guideline and independent analyses have documented major variability in actual GS-441524 content compared with labeled amounts, especially in oral formulations. (academic.oup.com)

Treatment duration is another area in flux. The traditional approach has been roughly 12 weeks of antiviral therapy, in part because the eyes and central nervous system are considered harder-to-penetrate compartments and therefore higher-risk sites for undertreatment or relapse. Newer discussion in the profession is exploring whether higher-dose induction protocols might reduce viral burden faster and allow shorter treatment in selected cats, but the caution is that early clinical improvement does not necessarily mean viral clearance. That has increased interest in more objective stopping criteria, including trends in serum amyloid A, alpha-1 acid glycoprotein, and the albumin:globulin ratio, rather than relying on appetite, weight gain, or owner impression alone.

Industry and professional commentary reflects that same mix of optimism and caution. Coverage in dvm360 described compounded oral GS-441524 availability in the U.S. as a major access change for practice, while also reiterating the FDA’s position that enforcement discretion is not the same as approval. In another dvm360 report, University of Illinois neurology resident Katelynn Ondek, DVM, PhD, called the new compounded oral medication a “game-changer” for veterinary medicine, highlighting how quickly frontline sentiment has shifted as legal prescribing options have expanded. Podcast and CE discussions for practitioners are also increasingly focused on “real practice” questions: how to make a presumptive diagnosis when definitive confirmation is uncommon, how to counsel clients on expected response, and how to balance urgency with the still-limited quality of the evidence. (dvm360.com)

Why it matters: For general practitioners, emergency clinicians, internists, and ophthalmology teams, ocular FIP now demands a different clinical mindset. Eye changes such as uveitis, hyphema, corneal edema, anisocoria, iris color change, retinal lesions, or vision loss may be part of systemic FIP rather than a standalone ophthalmic problem, and they can influence antiviral dosing decisions. That raises the stakes for prompt recognition, appropriate diagnostics, realistic prognosis discussions, and close monitoring of both systemic and ocular response. It also means pet parent conversations should cover the limits of the evidence, the compounded status of available U.S. GS-441524 products, and the possibility that some residual ocular damage may persist even when infection is controlled. (academic.oup.com)

There’s also a pharmacology and stewardship angle. As treatment becomes more mainstream, veterinarians will be under more pressure to distinguish among GS-441524, remdesivir, and rescue or alternative protocols, while accounting for formulation quality, absorption, adherence, and relapse risk. Reviews published in 2025 suggest high overall promise for GS-441524, but they also call for randomized controlled trials and more evidence-based protocols tailored to specific presentations, including ocular and neurologic disease. At the same time, practical discussions are shifting toward how to individualize dosing and duration without overinterpreting early response or relying too heavily on nonstandardized products. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next phase will likely center on protocol refinement, including whether shorter courses are appropriate for selected cats, how best to dose ocular and neurologic cases, whether biomarker-guided treatment termination can be validated in broader practice, and whether U.S. compounded products generate outcomes comparable to the formulations used in published international studies. (wormsandgermsblog.com)